Jazz Pharmaceuticals Share Price Pullback: Undervalued Opportunity?
ByAinvest
Saturday, Jan 31, 2026 2:34 pm ET1min read
JAZZ--
Jazz Pharmaceuticals shares are currently undervalued by 78.8% according to a discounted cash flow analysis, with a fair value of $776.08 per share. The share price has pulled back by 5.0% year to date, but has a 32.3% return over the past year. The company's value score is 6/6, indicating a strong value story.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet